PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
Revenue of PaxMedica, Inc. Common Stock (PXMD)
Revenue in 2023 (TTM): $
According to PaxMedica, Inc. Common Stock's latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of PaxMedica, Inc. Common Stock
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $ | $-16,145,270 | $-18,289,725 | $-18,289,725 |
| 2022 | $ | $ | $-10,604,430 | $-14,801,767 | $-14,801,767 |
| 2021 | $ | $ | $-7,197,800 | $-10,228,971 | $-13,034,827 |
| 2020 | $ | $ | $-5,619,387 | $-7,826,008 | $-8,489,007 |
| 2019 | $ | $ | $-598,609 | $-598,609 | $-598,609 |